SAB Biotherapeutics (SABSW) Accumulated Depreciation & Amortization (2020 - 2025)
SAB Biotherapeutics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $17.5 million for Q4 2025.
- For Q4 2025, Accumulated Depreciation & Amortization rose 20.19% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $17.5 million, up 20.19%, while the annual FY2025 figure was $17.5 million, 20.19% up from the prior year.
- Accumulated Depreciation & Amortization reached $17.5 million in Q4 2025 per SABSW's latest filing, up from $16.8 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $17.5 million in Q4 2025 to a low of -$17.9 million in Q1 2022.
- Average Accumulated Depreciation & Amortization over 5 years is $6.7 million, with a median of $9.9 million recorded in 2023.
- Peak YoY movement for Accumulated Depreciation & Amortization: fell 21.97% in 2021, then soared 149.07% in 2023.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$16.9 million in 2021, then soared by 137.19% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 20.19% to $17.5 million in 2025.
- Per Business Quant, the three most recent readings for SABSW's Accumulated Depreciation & Amortization are $17.5 million (Q4 2025), $16.8 million (Q3 2025), and $16.1 million (Q2 2025).